AKR1C3 and acute lymphoblastic leukemia: Contrary to these studies, we have shown that more potent AKR1C3 inhibitors with greater isoform selectivity reverse drug resistance to etoposide11, daunorubicin, and cytarabine in AML cells and patient-derived T-ALL cells10.